Clinical Trial Update: Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine [Phase 2]

View source ↗

Summary

This Phase 2 trial reports safety and immunogenicity data for a new formulation of a bivalent killed, whole-cell oral cholera vaccine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholera

Drugs mentioned

• Bivalent killed, whole-cell oral cholera vaccine (new formulation)

Snippet

Sponsor: International Vaccine Institute | Conditions: Cholera | Phase 2 | Status: COMPLETED